A profile on capmatinib in treating adult patients with metastatic NSCLC tumors with MET exon 14 skipping mutations

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 24;553(7689):446–454. PubMed PMID: 29364287.
   PubMed Web of Science ®Google Scholar
• Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021 Aug;27(8):1345–1356. PubMed PMID: 34385702.
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012 Jan 24;12(2):89–103. PubMed PMID: 22270953.
   PubMed Web of Science ®Google Scholar
• Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020 Sep;17(9):569–587. PubMed PMID: 32514147; PubMed Central PMCID: PMCPMC7478851
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018 Jun;18(6):341–358. PubMed PMID: 29674709.
   PubMed Web of Science ®Google Scholar
• Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016 Jun 15;22(12):3048–3056. PubMed PMID: 26847053.
   PubMed Web of Science ®Google Scholar
• Recondo G, Che J, Janne PA, et al. Targeting MET dysregulation in cancer. Cancer Discov. 2020 Jul;10(7):922–934. PubMed PMID: 32532746; PubMed Central PMCID: PMCPMC7781009.
   PubMed Web of Science ®Google Scholar
• Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020 Sep 3;383(10):944–957. PubMed PMID: 32877583.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016 Sep;11(9):1493–1502. PubMed PMID: 27343443
   PubMed Web of Science ®Google Scholar
• Wolf J, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study. Presented at: American Society of Clinical Oncology; 2021 June 4–8; Chicago, USA.
   Google Scholar
• Kron A, Scheffler M, Heydt C, et al. Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy. J Thorac Oncol. 2021 Apr;16(4):572–582. PubMed PMID: 33309988
   PubMed Web of Science ®Google Scholar
• Fujino T, Kobayashi Y, Suda K, et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J Thorac Oncol. 2019 Oct;14(10):1753–1765. PubMed PMID: 31279006
   PubMed Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020 Sep 3;383(10):931–943. PubMed PMID: 32469185.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information (Tabrecta). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf
   Google Scholar
• Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127–7138. PubMed PMID: 21918175.
   PubMed Web of Science ®Google Scholar
• Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019 May 15;25(10):3164–3175. PubMed PMID: 30674502.
   PubMed Web of Science ®Google Scholar
• Glaenzel U, Jin Y, Hansen R, et al. Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite. Drug Metab Dispos. 2020 Oct;48(10):873–885. PubMed PMID: 32665418
   PubMed Web of Science ®Google Scholar
• Bang YJ, Su WC, Schuler M, et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci. 2020 Feb;111(2):536–547. PubMed PMID: 31778267; PubMed Central PMCID: PMCPMC7004521
   PubMed Web of Science ®Google Scholar
• Esaki T, Hirai F, Makiyama A, et al. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors. Cancer Sci. 2019 Apr;110(4):1340–1351. PubMed PMID: 30724423; PubMed Central PMCID: PMCPMC6447844
   PubMed Web of Science ®Google Scholar
• Moreno V, Greil R, Yachnin J, et al. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. Clin Ther. 2021 May 27;43:1092–1111. PubMed PMID: 34053700.
   PubMed Web of Science ®Google Scholar
• Grande E, Giovannini M, Marriere E, et al. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol. 2021 Jul;87(7):2867–2878. PubMed PMID: 33300203; PubMed Central PMCID: PMCPMC8359310
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Moonsamy P, Gainor JF, et al. A phase 2 study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor. J Thorac Oncol. 2021 May;16(5):850–859. PubMed PMID: 33545388
   PubMed Web of Science ®Google Scholar
• Recondo G, Bahcall M, Spurr LF, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC. Clin Cancer Res. 2020 Jun 1;26(11):2615–2625. PubMed PMID: 32034073.
   PubMed Web of Science ®Google Scholar
• Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 Oct 1;29(10):2085–2091. PubMed PMID: 30165371; PubMed Central PMCID: PMCPMC6225900.
   PubMed Web of Science ®Google Scholar
• Reis H, Metzenmacher M, Goetz M, et al. MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clin Lung Cancer. 2018 Jul;19(4):e441–e463. PubMed PMID: 29631966
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 Aug 1;30(8):1321–1328. PubMed PMID: 31125062; PubMed Central PMCID: PMCPMC7389252.
   PubMed Web of Science ®Google Scholar
• Mayenga M, Assie JB, Monnet I, et al. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: a series of 6 cases. Lung Cancer. 2020 Dec;150:21–25. PubMed PMID: 33045465
   PubMed Web of Science ®Google Scholar
• Scotcher D, Arya V, Yang X, et al. Mechanistic models as framework for understanding biomarker disposition: prediction of creatinine-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2020 May;9(5):282–293. PubMed PMID: 32410382; PubMed Central PMCID: PMCPMC7239336.
   PubMedGoogle Scholar
• Chu X, Bleasby K, Chan GH, et al. Transporters affecting biochemical test results: creatinine-drug interactions. Clin Pharmacol Ther. 2016 Nov;100(5):437–440. PubMed PMID: 27509262
   PubMed Web of Science ®Google Scholar
• Chu X, Bleasby K, Chan GH, et al. The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist? Drug Metab Dispos. 2016 Sep;44(9):1498–1509. PubMed PMID: 26825641
   PubMedGoogle Scholar
• Mohan A, Herrmann SM. Capmatinib-induced pseudo-acute kidney injury: a case report. Am J Kidney Dis. 2021 Jun 9. PubMed PMID: 34118303. 10.1053/j.ajkd.2021.04.009
   Web of Science ®Google Scholar
• Kanemura H, Takeda M, Shimizu S, et al. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14. Thorac Cancer. 2021 Feb;12(4):549–552. PubMed PMID: 33347701; PubMed Central PMCID: PMCPMC7882388
   PubMed Web of Science ®Google Scholar
• Cai B, Zhou ZY, Xue W, et al. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States. J Med Econ. 2021 Jan-Dec;24(1):131–139. PubMed PMID: 33397178
   PubMed Web of Science ®Google Scholar
• Kim CG, Cho BC, Lim SM. Sequencing of MET inhibitors in lung cancer: have we met the target? J Thorac Oncol. 2021 May;16(5):709–711. PubMed PMID: 33896567.
   PubMed Web of Science ®Google Scholar